Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

CERo Therapeutics Holdings Inc CERO

Healthcare Biotechnology
CERo Therapeutics Holdings, Inc. is an immunotherapy company advancing the development of engineered T cell therapeutics for the treatment of cancer. The Company’s proprietary approach to T cell engineering, enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, which is designed to engage the body’s full immune repertoire to achieve optimized cancer therapy. Its cellular immunotherapy platform is focused on redirecting patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating CERo, which is referred to as chimeric engulfment receptor t cells (CER-T). The Company is initiating clinical trials for its lead product candidate, CER-1236, for hematological malignancies.


NDAQ:CERO - Post by User

CERo Therapeutics Holdings Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(72)
•••
Post by Iseneschalon Nov 11, 2024 9:23am
42 Views
Post# 36306334

CERO..... Todays NR states what we already know

CERO..... Todays NR states what we already knowBe careful here....Co is Nasdaq MVLS requirement deficient and also is going to raise money via S1 dated May 01/26

MVLS ..... https://www.sec.gov/Archives/edgar/data/1870404/000121390024093570/ea0219564-8k_cerothera.htm

S1 ........... https://www.sec.gov/Archives/edgar/data/1870404/000121390024093576/ea021956402-424b3_cero.htm

Make note: The share price can still rally ....now at 20 cents

Me ..no position
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities